Sensorion (ALSEN) Corporate Presentation summary

Vision and strategy

• Aims to address inner ear hearing disorders, enabling people to live with unlimited connections.

• Focuses on advanced therapies, including gene therapies and small molecules, for hearing loss.

• Pursues a modality-agnostic approach and leverages exclusive global partnerships.

• Pipeline targets multiple indications and upcoming clinical milestones.

• Supported by leading life sciences shareholders and a strong internal team.

Leadership, partnerships, and capabilities

• Leadership team has deep experience in genetic diseases, investment banking, and product delivery.

• Board and scientific advisory board include global experts in hearing research and biotech.

• Collaborates with Institut Pasteur and clinical centers of excellence for research and trials.

• Internal capabilities span preclinical, clinical, regulatory, and patient access functions.

• Over 600 subjects enrolled in clinical trials, with expertise in gene therapy and audiology.

Pipeline overview and clinical programs

• Pipeline includes SENS-501 (Otoferlin deficiency), GJB2-GT (various GJB2-related hearing losses), and SENS-401 (multiple indications).

• SENS-501 and GJB2-GT are gene therapies targeting rare auditory diseases.

• SENS-401 is a small molecule for hearing preservation and prevention.

• Multiple programs are in preclinical, Phase 1/2, and Phase 2 stages.

• Key milestones include cohort completions, data readouts, and clinical trial applications.